- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07946926
Adaptation of Facilitated Access to Mutual Aid for Community Alcohol and Drug Services (FAMA)
Adaptation of a Facilitated Access to Mutual Aid (FAMA) Intervention for Adults Accessing Community Alcohol and Drug Services in England.
Alcohol and other drug (AOD) use disorders are associated with a range of adverse outcomes. Relapse following AOD treatment is common. Attendance at Mutual Aid Groups (MAGs) is associated with improved health outcomes and reduced healthcare utilisation costs. National guidance recommends that clinical staff promote MAG attendance, but few patients are referred to, or attend, MAGs. An intensive referral intervention, developed in the United States of America has been shown to increase engagement with MAGs. The aim of this National Institute for Health Research (NIHR)-funded study is to adapt and test a Facilitated Access to Mutual Aid (FAMA) intervention and staff training for delivery in community AOD services in England.
Phase one of this study consists of qualitative focus groups conducted with staff of community AOD services and adults receiving AOD treatment. Eight focus groups will explore participants' views of MAGs and the existing American FAMA intervention. The FAMA intervention will then be adapted and staff training developed, based on the focus group findings and input from patient and public involvement and engagement (PPIE) groups.
Phase two of this study consists of testing the adapted FAMA intervention. Staff in one community AOD service will receive the newly developed FAMA training. They will deliver FAMA to people who are currently receiving AOD treatment service. Each session will be recorded and the fidelity of intervention delivery will be assessed by the research team using a checklist. Staff and patient feedback will be collected using brief questionnaires in informal feedback sessions. The FAMA intervention will be refined and delivered again with another round of feedback being collected. A final version of the FAMA intervention will then be agreed by the research team and PPIE groups.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adults aged 18+ years who are accessing AOD treatment and staff, aged 18+ years who are working in paid client facing role in an AOD treatment service.
Beskrivning
Phase one (staff) inclusion criteria:
- Aged 18+ years
- Currently working in a paid client facing role in an AOD treatment service
Phase one (people accessing AOD treatment) inclusion criteria:
- Aged 18+ years
- Currently receiving treatment from an AOD treatment service
Phase two (staff) inclusion criteria:
- Aged 18+ years
- Currently working as a keyworker or recover worker in an AOD treatment service
Phase two (people accessing AOD treatment) inclusion criteria:
- Aged 18+ years
- Currently receiving treatment from an AOD treatment service
- On a participating staff member's caseload
- Not attending MAGs.
Exclusion Criteria:
- N/A
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: OTHER
- Tidsperspektiv: CROSS_SECTIONAL
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Qualitative focus groups
Tidsram: Focus groups will last approximately 90 minutes
|
Qualitative focus groups |
Focus groups will last approximately 90 minutes
|
|
Acceptability of Intervention measure (AIM) adapted for FAMA
Tidsram: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be acceptable |
Maximum 10 weeks from enrolment in the study
|
|
Feasibility of Intervention (FIM) adapted for FAMA
Tidsram: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be feasible |
Maximum 10 weeks from enrolment in the study
|
|
Appropriateness Measure (IAM) adapted for FAMA
Tidsram: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be appropriate |
Maximum 10 weeks from enrolment in the study
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IRAS 370125
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .